199 related articles for article (PubMed ID: 15103391)
1. The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.
Polito L; Bolognesi A; Tazzari PL; Farini V; Lubelli C; Zinzani PL; Ricci F; Stirpe F
Leukemia; 2004 Jul; 18(7):1215-22. PubMed ID: 15103391
[TBL] [Abstract][Full Text] [Related]
2. CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia.
Bolognesi A; Polito L; Farini V; Bortolotti M; Tazzari PL; Ratta M; Ravaioli A; Horenstein AL; Stirpe F; Battelli MG; Malavasi F
J Biol Regul Homeost Agents; 2005; 19(3-4):145-52. PubMed ID: 16602630
[TBL] [Abstract][Full Text] [Related]
3. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
4. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors.
Cazzola M; Bergamaschi G; Dezza L; D'Uva R; Ponchio L; Rosti V; Ascari E
Cancer Res; 1991 Jan; 51(2):536-41. PubMed ID: 1985771
[TBL] [Abstract][Full Text] [Related]
6. ATG-saporin-S6 immunotoxin: a new potent and selective drug to eliminate activated lymphocytes and lymphoma cells.
Polito L; Bortolotti M; Farini V; Pedrazzi M; Tazzari PL; Bolognesi A
Br J Haematol; 2009 Dec; 147(5):710-8. PubMed ID: 19764990
[TBL] [Abstract][Full Text] [Related]
7. Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells.
Polito L; Mercatelli D; Bortolotti M; Maiello S; Djemil A; Battelli MG; Bolognesi A
Toxins (Basel); 2017 May; 9(6):. PubMed ID: 28556822
[TBL] [Abstract][Full Text] [Related]
8. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.
Alas S; Bonavida B; Emmanouilides C
Anticancer Res; 2000; 20(5A):2961-6. PubMed ID: 11062708
[TBL] [Abstract][Full Text] [Related]
10. High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin.
Bortolotti M; Bolognesi A; Battelli MG; Polito L
Toxins (Basel); 2016 Jun; 8(6):. PubMed ID: 27338475
[TBL] [Abstract][Full Text] [Related]
11. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis.
Bergamaschi G; Perfetti V; Tonon L; Novella A; Lucotti C; Danova M; Glennie MJ; Merlini G; Cazzola M
Br J Haematol; 1996 Jun; 93(4):789-94. PubMed ID: 8703804
[TBL] [Abstract][Full Text] [Related]
12. Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies.
Sforzini S; Bolognesi A; Meazza R; Marciano S; Tazzari PL; Stein H; Stirpe F; Ferrini S
J Hematother; 1995 Oct; 4(5):429-32. PubMed ID: 8581380
[TBL] [Abstract][Full Text] [Related]
13. [Apoptosis of human B cell lymphoma Raji cells induced by monovalent anti-CD20 antibody].
Liu YX; Fan DM; Xiong DS; Xu YF; Shao XF; Xu YS; Peng H; Yang M; Qin L; Zhu ZP; Yang CZ
Ai Zheng; 2003 Dec; 22(12):1249-53. PubMed ID: 14693045
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
15. Polynucleotide: adenosine glycosidase activity of immunotoxins containing ribosome-inactivating proteins.
Barbieri L; Bolognesi A; Valbonesi P; Polito L; Olivieri F; Stirpe F
J Drug Target; 2000; 8(5):281-8. PubMed ID: 11328656
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo efficacy of heat shock protein specific immunotoxins on human tumor cells.
Piselli P; Vendetti S; Poccia F; Cicconi R; Mattei M; Bolognesi A; Stirpe F; Colizzi V
J Biol Regul Homeost Agents; 1995; 9(2):55-62. PubMed ID: 9127634
[TBL] [Abstract][Full Text] [Related]
17. Different sensitivity of CD30+ cell lines to Ber-H2/saporin-S6 immunotoxin.
Battelli MG; Bolognesi A; Olivieri F; Polito L; Stirpe F
J Drug Target; 1998; 5(3):181-91. PubMed ID: 9606008
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
[TBL] [Abstract][Full Text] [Related]
19. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
20. Immunotoxin-mediated inhibition of chronic lymphocytic leukemia cell proliferation in humans.
Siena S; Bregni M; Formosa A; Brando B; Marenco P; Lappi DA; Bonadonna G; Gianni AM
Cancer Res; 1989 Jun; 49(12):3328-32. PubMed ID: 2785850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]